title: Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.
abstract: The transforming growth factor-beta (TGF-beta) receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. In many cancers, expression of TGF-beta type II receptor (TbetaR-II) is markedly decreased. In the present study, we show that the hepatocytes isolated from 15-day-old, but not 9-month-old, mice heterozygous for the deletion of the TbetaR-II gene are slightly less sensitive to the growth-inhibitory effect of TGF-beta when compared with wild-type littermates of same age. In addition, the proliferation index of hepatocytes as indicated by bromodeoxyuridine incorporation is mildly increased in the heterozygous mice. These subtle changes in cellular phenotype did not result in either gross or microscopic abnormality of the liver. The treatment of these mice with the chemical carcinogen, diethylnitrosamine, results in a significantly enhanced tumorigenesis in the liver when compared with the wild-type littermates. Our results demonstrate the gene-dosage effect of TbetaR-II and indicate that the reduced expression of TbetaR-II in mice increases susceptibility to tumorigenesis in the liver.
authors.affiliation: Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892-5055, USA.
authors.forename: Y H
authors.initials: YH
authors.lastname: Im
authors.forename: H T
authors.initials: HT
authors.lastname: Kim
authors.forename: I Y
authors.initials: IY
authors.lastname: Kim
authors.forename: V M
authors.initials: VM
authors.lastname: Factor
authors.forename: K B
authors.initials: KB
authors.lastname: Hahm
authors.forename: M
authors.initials: M
authors.lastname: Anzano
authors.forename: J J
authors.initials: JJ
authors.lastname: Jang
authors.forename: K
authors.initials: K
authors.lastname: Flanders
authors.forename: D C
authors.initials: DC
authors.lastname: Haines
authors.forename: S S
authors.initials: SS
authors.lastname: Thorgeirsson
authors.forename: A
authors.initials: A
authors.lastname: Sizeland
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
mesh_terms: D000818:Animals; D002273:Carcinogens; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D004052:Diethylnitrosamine; D005260:Female; D018628:Gene Dosage; D018816:Genes, cdc / Q000502:physiology; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010634:Phenobarbital / Q000494:pharmacology; D011247:Pregnancy; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics; D053773:Transforming Growth Factor beta1
chemical_list: D002273:Carcinogens; D012333:RNA, Messenger; D018125:Receptors, Transforming Growth Factor beta; C508961:Tgfb1 protein, mouse; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D004052:Diethylnitrosamine; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D010634:Phenobarbital